Loading...
XJPX2269
Market cap5.19bUSD
Dec 24, Last price  
3,136.00JPY
1D
-0.66%
1Q
-13.11%
Jan 2017
-65.70%
IPO
90.42%
Name

Meiji Holdings Co Ltd

Chart & Performance

D1W1MN
XJPX:2269 chart
P/E
16.07
P/S
0.74
EPS
195.18
Div Yield, %
3.25%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
-2.50%
Revenues
1.11t
+4.08%
710,908,000,000702,750,000,000706,988,000,000711,394,000,0001,106,655,000,0001,114,095,000,0001,109,275,000,0001,126,520,000,0001,148,076,000,0001,161,152,000,0001,223,746,000,0001,242,480,000,0001,240,860,000,0001,254,380,000,0001,252,706,000,0001,191,765,000,0001,013,092,000,0001,062,157,000,0001,105,494,000,000
Net income
50.68b
-27.01%
10,055,000,00013,708,000,0009,226,000,0005,933,000,00013,088,000,0009,552,000,0006,805,000,00016,646,000,00019,060,000,00030,891,000,00062,580,000,00060,786,000,00061,278,000,00061,868,000,00067,318,000,00065,655,000,00087,497,000,00069,424,000,00050,675,000,000
CFO
107.98b
+27.02%
31,256,000,00037,123,000,00018,542,000,00016,991,000,00047,707,000,00057,995,000,00030,597,000,00050,622,000,00063,847,000,00086,487,000,000105,155,000,00081,888,000,000108,775,000,000112,100,000,000114,103,000,000123,683,000,000127,526,000,00085,013,000,000107,983,000,000
Dividend
Mar 28, 20250 JPY/sh
Earnings
Feb 06, 2025

Profile

Meiji Holdings Co., Ltd., through its subsidiaries, manufactures and sells dairy products, confectioneries, nutritional products, and pharmaceuticals in Japan and internationally. The company operates through two segments, Food and Pharmaceutical. It provides yogurt, cheese, drinking milk, beverages, butter and margarine, cream, ice cream, ready meals, chocolates, gummy products, chewing gums, sports nutrition products, infant formula, liquid diet, beauty supplements, OTC medicines, feed stuffs, corn sweeteners, and sugar, as well as transportation and distribution services. The company also offers drugs for infectious diseases and central nervous system disorders, as well as generic drugs; agricultural and livestock chemicals; human and animal vaccines, and blood plasma products; and veterinary drugs for livestock and fisheries comprising antimicrobial injection, disinfectants, oral administration, insecticides, anthelmintic, antipyretic, analgesic, anti-inflammatory, hemostatic, and breeding agents. In addition, it provides insecticides, metabolites, feed additives, and mixed feed; and companion animals, including anesthetics and painkillers, anti-parasitic and gastrointestinal drugs, anti-bacterial agents, antiplasmin agents, vitamin E preparations, and dietary supplements. Meiji Holdings Co., Ltd. was founded in 1916 and is headquartered in Tokyo, Japan.
URL
https://www.meiji.com/
IPO date
Apr 01, 2009
Employees
17,290
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑032015‑03
Income
Revenues
1,105,494,000
4.08%
1,062,157,000
4.84%
1,013,092,000
-14.99%
Cost of revenue
1,021,172,000
997,370,000
930,844,000
Unusual Expense (Income)
NOPBT
84,322,000
64,787,000
82,248,000
NOPBT Margin
7.63%
6.10%
8.12%
Operating Taxes
33,792,000
23,912,000
36,069,000
Tax Rate
40.07%
36.91%
43.85%
NOPAT
50,530,000
40,875,000
46,179,000
Net income
50,675,000
-27.01%
69,424,000
-20.66%
87,497,000
33.27%
Dividends
(26,444,000)
(24,606,000)
(23,898,000)
Dividend yield
2.80%
2.80%
1.30%
Proceeds from repurchase of equity
1,057,000
(4,682,000)
(29,754,000)
BB yield
-0.11%
0.53%
1.61%
Debt
Debt current
22,330,000
14,874,000
28,227,000
Long-term debt
31,474,000
53,461,000
53,739,000
Deferred revenue
56,331,000
54,735,000
Other long-term liabilities
62,803,000
7,326,000
4,474,000
Net debt
(140,989,000)
(136,818,000)
(138,483,000)
Cash flow
Cash from operating activities
107,983,000
85,013,000
127,526,000
CAPEX
(53,444,000)
(72,170,000)
(93,165,000)
Cash from investing activities
(24,604,000)
(36,788,000)
(27,614,000)
Cash from financing activities
(43,772,000)
(54,734,000)
(76,997,000)
FCF
40,516,000
10,212,000
38,029,000
Balance
Cash
106,858,000
63,519,000
67,409,000
Long term investments
87,935,000
141,634,000
153,040,000
Excess cash
139,518,300
152,045,150
169,794,400
Stockholders' equity
697,419,000
1,383,351,000
1,303,257,000
Invested Capital
761,000,700
715,991,850
663,558,600
ROIC
6.84%
5.93%
6.97%
ROCE
9.31%
7.42%
9.81%
EV
Common stock shares outstanding
278,984
278,778
278,778
Price
3,386.00
7.32%
3,155.00
-52.27%
6,610.00
-7.16%
Market cap
944,639,824
7.40%
879,544,590
-52.27%
1,842,722,580
-7.16%
EV
844,911,824
1,447,269,590
2,376,796,580
EBITDA
139,650,000
118,377,000
132,366,000
EV/EBITDA
6.05
12.23
17.96
Interest
367,000
462,000
500,000
Interest/NOPBT
0.44%
0.71%
0.61%